Leverkusen, Germany - Biofrontera AG (DSE: B8F) has today published its interim report for the third quarter of 2012 on the corporate webpage. The report focuses on the company development; detailed financial figures are not being published at the end of this period.
The overruling theme of the ongoing commercial year is the marketing of Ameluz®, Biofrontera`s prescription drug for the treatment of actinic keratosis. Ameluz® was approved by the European Commission for EU-wide marketing and distribution in December 2011. Since February 2012 Ameluz® is distributed in Germany through Biofrontera`s own sales force. Based on license and supply agreements formed during the year, the medicinal product was also launched in Denmark, Sweden, Norway, The Netherlands, the United Kingdom and Austria after the summer break, partly after the reporting period. While first results of these countries are still outstanding, the success is becoming apparent in Germany. Particularly in recent months, sales of Ameluz® escalated.
The interim report provides detailed information on the progress of Ameluz® marketing as well as other aspects of the corporate development. Revenues of the first three quarters of 2012 amounted to TEUR 2,653, of which TEUR 1,550 were one-time license payments.
The liquidity at the beginning of the year was TEUR 554, at the end of the reporting period EUR 4.5 mln.
Since August Biofrontera`s shares are trading on the regulated market of the Frankfurt stock exchange (Frankfurter Wertpapierbörse) in addition to the listing at the regulated market of the Düsseldorf stock exchange. Since reporting obligations are identical, there is no change for Biofrontera. Share liquidity, which is particularly relevant for major shareholders, increased to an average daily trading volume of more than 26,000 shares.
About Biofrontera AG
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The Biofrontera group aims at attending and treating the skin, recognizing the aesthetic needs of a person`s visual reflection. Biofrontera is listed at the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.
For further information please contact:
Anke zur Mühlen
Director IR & PR
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany